US 12,331,338 B2
Compositions and methods for enhancing reverse transcriptase activity and/or reducing the inhibition of reverse transcriptase
Xiangdong Meng, Albany, CA (US); Xiaosong Gong, Richmond, CA (US); and Cindy C T Wan, San Francisco, CA (US)
Assigned to BIO-RAD LABORATORIES, INC., Hercules, CA (US)
Filed by BIO-RAD LABORATORIES, INC., Hercules, CA (US)
Filed on Mar. 1, 2023, as Appl. No. 18/176,502.
Application 18/176,502 is a continuation of application No. 16/911,421, filed on Jun. 25, 2020, granted, now 11,597,920.
Claims priority of provisional application 62/866,182, filed on Jun. 25, 2019.
Prior Publication US 2023/0257731 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/12 (2006.01); C12N 9/96 (2006.01); C12N 15/11 (2006.01)
CPC C12N 9/96 (2013.01) [C12N 9/1276 (2013.01); C12N 15/11 (2013.01); C12Y 207/07049 (2013.01); C12N 2310/315 (2013.01)] 14 Claims
 
1. A composition comprising: a buffer, dNTPs, oligonucleotide dTn, where n is an integer selected from 5, 6, 7, 8, 9, 10, 11 or 12, potassium glutamate, poloxamer 188, polyvinyl sulfonic acid (PVSA), and one or more oligonucleotides selected from: X1-X2-X3-X4-X5, X1-X2-X3-X4-X5-X6, X1-X2-X3-X4-X5-X6-X7, X1-X2-X3-X4-X5-X6-X7-X8, X1-X2-X3-X4-X5-X6-X7-X8-X9, X1-X2-X3-X4-X5-X6-X7-X8-X9-X10 (SEQ ID NO: 21), X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11 (SEQ ID NO: 22), and X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12 (SEQ ID NO: 23), and wherein:
X1-X2-X3-X4-X5 are: i) randomly ordered A and T nucleotides; ii) randomly ordered G and C nucleotides; or iii) at least one but less than five of the nucleotides are randomly selected from the group consisting of: A and T, while the remaining nucleotides are randomly selected G and C nucleotides;
X1-X2-X3-X4-X5-X6 are: i) randomly ordered A and T nucleotides; ii) randomly ordered G and C nucleotides; or iii) at least one but less than six of the nucleotides are randomly selected from the group consisting of: A and T, while the remaining nucleotides are randomly selected G and C nucleotides;
X1-X2-X3-X4-X5-X6-X7 are: i) randomly ordered A and T nucleotides; ii) randomly ordered G and C nucleotides; or iii) at least one but less than seven of the nucleotides are randomly selected from the group consisting of: A and T, while the remaining nucleotides are randomly selected G and C nucleotides;
X1-X2-X3-X4-X5-X6-X7-X8 are: i) randomly ordered A and T nucleotides; ii) randomly ordered G and C nucleotides; or iii) at least one but less than eight of the nucleotides are randomly selected from the group consisting of: A and T, while the remaining nucleotides are randomly selected G and C nucleotides;
X1-X2-X3-X4-X5-X6-X7-X8-X9 are: i) randomly ordered A and T nucleotides; ii) randomly ordered G and C nucleotides; or iii) at least one but less than nine of the nucleotides are randomly selected from the group consisting of: A and T, while the remaining nucleotides are randomly selected G and C nucleotides;
X1-X2-X3-X4-X5-X6-X7-X8-X9-X10 (SEQ ID NO: 21) are: i) randomly ordered A and T nucleotides; ii) randomly ordered G and C nucleotides; or iii) at least one but less than ten of the nucleotides are randomly selected from the group consisting of: A and T, while the remaining nucleotides are randomly selected G and C nucleotides;
X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11 (SEQ ID NO: 22) are: i) randomly ordered A and T nucleotides; ii) randomly ordered G and C nucleotides; or iii) at least one but less than eleven of the nucleotides are randomly selected from the group consisting of: A and T, while the remaining nucleotides are randomly selected G and C nucleotides; and
X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12 (SEQ ID NO: 23) are: i) randomly ordered A and T nucleotides; ii) randomly ordered G and C nucleotides; or iii) at least one but less than twelve of the nucleotides are randomly selected from the group consisting of: A and T, while the remaining nucleotides are randomly selected G and C nucleotides.